Beta-Blockers for Pyogenic Granuloma: A Systematic Review of Case Reports, Case Series, and Clinical Trials

J Drugs Dermatol. 2019 Oct 1;18(10):1006-1010.

Abstract

Pyogenic granuloma (PG) is an acquired vascular growth on the skin and mucous membranes. Even though PG is a benign tumor, treatment is required due to associated risk of ulceration and bleeding, cosmetic concerns, and the low likelihood of spontaneous regression. Treatment entails excisional surgery, cryotherapy, or electrocautery; recurrence however is a major problem. Beta-blockers became an attractive option for the treatment of vascular growths after it got approved for infantile hemangioma. PG was found to express beta adrenergic receptors, similarly to infantile hemangioma. Several publications have reported the use of oral and topical beta blockers such as timolol, propranolol, and betaxolol for the treatment of PG. In this study, we summarized the literature with regards to the effectiveness of topical beta blockers for the treatment of PG, and discussed all published case reports, case series, and open-label single arm trials. J Drugs Dermatol. 2019;18(10):1006-1010.

Publication types

  • Systematic Review

MeSH terms

  • Administration, Cutaneous
  • Administration, Oral
  • Adrenergic beta-Antagonists / therapeutic use*
  • Betaxolol / therapeutic use
  • Clinical Trials as Topic
  • Granuloma, Pyogenic / drug therapy*
  • Granuloma, Pyogenic / pathology
  • Humans
  • Propranolol / therapeutic use
  • Receptors, Adrenergic, beta / metabolism
  • Recurrence
  • Skin / pathology
  • Skin Diseases / drug therapy*
  • Skin Diseases / pathology
  • Timolol / therapeutic use
  • Treatment Outcome

Substances

  • Adrenergic beta-Antagonists
  • Receptors, Adrenergic, beta
  • Timolol
  • Propranolol
  • Betaxolol